Xarelto Lawsuit Plaintiffs Allege 4 Years Without An Available Antidote Is Negligent

April 25, 2016 – – BloodThinnerHelp.com comments on a common point of concern for plaintiffs involved in Xarelto bleeding lawsuits. Thousands of plaintiffs who have filed suit against the new-generation anticoagulant allege that the drug’s manufacturers, Bayer AG, and Janssen Pharmaceuticals showed severe negligence by neglecting to release the blood thinner to market with a corresponding antidote.

Xarelto was released in 2011 after approval by the U.S. Food and Drug Administration. It was approved to treat patients suffering from deep vein thrombosis, pulmonary embolism, or atrial fibrillation, as well as those who are recovering from hip and knee replacement surgeries. The drug was initially popular, as it provides users with freedoms other blood thinners had been unable to.

After many lawsuits surrounding the drug began to add up, however, many became concerned about the blood thinner’s lack of antidote, stating that it was a major issue. Because Xarelto went years without an available antidote, patients taking it who had suffered even minor injuries were reportedly in danger of significant bleeds which could become uncontrollable and even fatal. Those taking Xarelto who became injured would be unable to be treated with an antidote by their physicians.

Traditional blood thinners, quite differently, were released to the market with an available antidote in vitamin K. Patients taking these blood thinners, therefore, who become injured and are bleeding are able to be treated with vitamin K by their physicians. This treatment will counter the effects of the blood thinner and will allow the patient’s blood to clot.

Today, lawsuits surrounding Xarelto have surpassed 3,400 in number. They have been formed into two major groupings: over 620 cases were consolidated in Philadelphia, Pennsylvania by the Court of Common Pleas forming a Mass Tort Program while more than 2,800 others cases have been transferred to a single court in Eastern Louisiana forming MDL Number 2592. Plaintiffs involved in these cases commonly allege that Xarelto use puts patients at increased risk for the development of severe and even fatal bleeding events.

As those involved anxiously await trial, Attorney Joseph Osborne is currently looking to help others who have taken the drug and who believe that it has caused them to suffer from health problems. He wants to help ensure that affected patients will be given the opportunity to fully evaluate their legal rights in the matter, as they may be entitled to substantial compensation. To better assist those who need it, Attorney Osborne is now offering complimentary legal consultations to qualified parties.

To ask questions or request further information concerning Xarelto litigation, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009596